Matthew S. Dietz
No Rating Available
(Learn About Our Rating System)

Matthew S. Dietz, DO, MSEd

Languages spoken: English

Clinical Locations

Primary Children's Hospital

Pediatric Hematology/Oncology
Salt Lake City

  • Dr. Dietz received his degrees in medicine and medical education from the University of New England. He completed his Pediatric Residency and Hematology and Oncology Fellowship at Oregon Health & Science University where he also served as chief resident.

    In 2020 Dr. Dietz joined the faculty of the University of Utah, where he is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. Clinically, Dr. Dietz focuses on the care of pediatric and young adult patients with bone and soft tissue sarcoma, as well as children with retinoblastoma. He is the Associate Director of the Primary Children's Hospital Solid Tumor Program and leads the Comprehensive Retinoblastoma Program. Dr. Dietz is committed to delivering cutting edge clinical care, as well as providing patients with access to experimental therapeutics and discovery programs.

    Dr. Dietz's research efforts include team science approaches to better understand the biology driving cancer progression and treatment resistance with a focus on translating this work into new therapies. He is a member of the Huntsman Cancer Institute's Experimental Therapeutics Program and actively involved in the development of early phase clinical trials through multiple cooperative consortia including the Children's Oncology Group, The Sunshine Project, the Pediatric Oncology Experimental Therapeutics Investigator's Consortium, and the Pediatric Early Phase Clinical Trial Network.

    Specialties

    Board Certification

    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Dr. Dietz received his degrees in medicine and medical education from the University of New England. He completed his Pediatric Residency and Hematology and Oncology Fellowship at Oregon Health & Science University where he also served as chief resident.

    In 2020 Dr. Dietz joined the faculty of the University of Utah, where he is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. Clinically, Dr. Dietz focuses on the care of pediatric and young adult patients with bone and soft tissue sarcoma, as well as children with retinoblastoma. He is the Associate Director of the Primary Children's Hospital Solid Tumor Program and leads the Comprehensive Retinoblastoma Program. Dr. Dietz is committed to delivering cutting edge clinical care, as well as providing patients with access to experimental therapeutics and discovery programs.

    Dr. Dietz's research efforts include team science approaches to better understand the biology driving cancer progression and treatment resistance with a focus on translating this work into new therapies. He is a member of the Huntsman Cancer Institute's Experimental Therapeutics Program and actively involved in the development of early phase clinical trials through multiple cooperative consortia including the Children's Oncology Group, The Sunshine Project, the Pediatric Oncology Experimental Therapeutics Investigator's Consortium, and the Pediatric Early Phase Clinical Trial Network.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Primary
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Graduate Training Human Investigations - Oregon Health & Science University Certificate
    Fellowship Pediatric Hematology/Oncology - Oregon Health & Science University Fellow
    Residency Pediatrics - Oregon Health & Science University Chief Resident
    Internship/Residency Pediatrics - Oregon Health & Science University Intern/Resident
    Graduate Training Medical Education - University of New England College of Osteopathic Medicine M.S.
    Professional Medical Osteopathic Medicine - University of New England College of Osteopathic Medicine D.O.
    Undergraduate Chemistry - Franklin & Marshall College B.A.

    Selected Publications

    Journal Article

    1. Deevyashali Parekh, Howard Lin, Akanksha Batajoo, Erin Peckham-Gregory, Vivekanudeep Karri, Whitney Stanton, Brooks Scull, Ryan Fleishmann, Nader El-Mallawany, Olive S Eckstein, Zachary D Prudowsky, Nitya Gulati, Jennifer E Agrusa, Asra Z Ahmed, Roland Chu, Matthew S Dietz, Stanton C Goldman, Michael D Hogarty, Hamayun Imran, Stefanos Intzes, Jenny M Kim, Lisa M Kopp, Carolyn Fein Levy, Philip Neff, Pallavi M Pillai, Bryan A Sisk, Deborah E Schiff, Angela D Trobaugh-Lotrario, Kelly Walkovich, Kenneth L McClain, Carl E Allen (2024). Clofarabine Monotherapy in Relapsed and Refractory Langerhans Cell Histiocytosis. Br J Haematol, (00), 1-6.
    2. McMahon NP, Jones JA, Anderson AN, Dietz MS, Wong MH, Gibbs SL (2023). Flexible Cyclic Immunofluorescence (cyCIF) Using Oligonucleotide Barcoded Antibodies. Cancers, 15(3).
    3. Dietz MS, Sutton TL, Walker BS, et al (2021). Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. Sci Rep, 11(13630).
    4. Dietz MS, Beach CZ, Barajas R, Parappilly MS, Sengupta SK, Baird LC, Ciporen JN, Han SJ, Loret de Mola R, Cho YJ, Nazemi KJ, McClelland S 3rd, Wong MH, Jaboin JJ (2020). Measure Twice: Promise of Liquid Biopsy in Pediatric High-Grade Gliomas. Adv Radiat Oncol, 5(2), 152-162. (Read full article)
    5. Lamble AJ, Dietz M, Laderas T, McWeeney S, Lind EF (2017). Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia. J Immunol Methods, 453, 44-52. (Read full article)
    6. Dietz M, Jones M, Svoboda M, Finanger E (2016). Case 3: Episodic Weakness in an 18-month-old Girl. Pediatr Rev, 37(5), 218-9. (Read full article)

    Review

    1. Vagher J, Dietz MS, Schiffman JD, Kohlmann W, Maese L (2022). Germline Predisposition to Soft Tissue Sarcoma. [Review]. Journal of Cancer Metastasis and Treatment, 8(31).